welcome clinically you Good business a morning, everyone. happy progress to our earnings had I'd Thank with to discuss our you, and to like update a Krystal. quarterly very and have We’ve call. to you. good chance quarter are
the issued the release with a summary business we of press results quarter. and Yesterday for update our financial
report Officer, XX-Q. be Form our filed Kellen We diamedica.com. Both Section our quarterly Financial also in Chief found Officer joined Harry website our Chief Scott can I'm our of Alcorn. at Investor the Dr. and Medical by documents today on
with trial or clinical CKD cohort is chronic This best possible and design company. our caused Let important scientific leaders ensure me the by other opinion Tuesday, X disease chronic to FDA significant our our On filed unmet advisory Phase kidney updating X advisors Phase months begin in for we multi for working rare or yesterday, protocol. with diseases. milestone our study. board kidney the spent protocol study the for on another disease We with and you key this
thousands complete of experienced from review advisory leverage now of from our The also protocol study in Phase of days KLKX to vast only board, we able to and expect body chronic patients KLKX treat used been able data and we to up here scientific enrollment of and our use which the draw were to on Xb hundreds XX not note the surrounding disease. XXXX. FDA the QX research knowledge Asia, completed that highly has in where would the has the insights of patient the the of to I with of recently clinical porcine kidney the start are
Before of I a details a viewed of that the filtration attribute design, in CKD combination a the patients. spend potentially to or glomerular with minute of discussing creatinine want trial into I to to the DMXXX the also sides unique is our the UACR community eGFR treatments, rate study, and albumin of the on urinary focusing for coin. as get Increasingly ratio scientific kidney two referred same understanding as the and or are damage function albuminuria kidney CKD estimated
Lancet more kidney Journal primarily published as been studies major of remarks. in function which consistent by year, from the is heard endpoint surrogate this now commissions is public a two eGFR. this attention And To of the for from has the drawing use with we FDA were Albuminuria date support in measured companion evaluating much disease. the progression albuminuria after earlier kidney what
therapies in in and being where UACR. eGFR we other today is albuminuria. the potentially used improvements data UACR data What demonstrated in an porcine and movements and short-term Asia, both we improve development both belief from as Xb saw eGFR clinical Phase significant currently in this to the to our base DMXXX DMXXX unique in has GFR signal believe as which that own potentially positive on compared simultaneously, well early KLKX is could We
suffering great kidney two study Phase patients UACR enroll Phase in eGFR changes from believe at will X who the to clinical could disease. X DMXXX in chronic if looking we trial, and be are patients will in is hypothesis and a we our We our correct, cohorts. be In benefit
second the is The first and one with non-diabetic IgA CKD and hypertension. African-Americans patient with nephropathy
target either approximately of micrograms for dose or XX patients enrollment at per level X weeks XX and Our a treated week. twice cohort two per be per will kilogram patients is administered subcutaneously
with UACR will standard safety of endpoints eGFR along and primary The markers. tolerability be and
filter cohorts by of IgA previously caused by The in blood. cells kidney in kidneys. forms on causing kidneys circulates is ability occurs to IgA system. a deposits be This diagnosed the of IgA the subjects cannot with considered disease pathogenic is buildup patient's IgA the faulty buildup by kidneys. autoimmune are cells The focused or impairs nephropathy disease pathogenic when first an and the response CKD that immune nephropathy. to mutated kidney This IgA inflammation that a the diagnosed patient's is result caused a processed which to the
Phase overall could thereby making in cells underlying on trial Approximately and products duration of treatment increasing months approved the a problem only it nephropathy are autoimmune by creating currently forms blood with the similar the for a XXX rare potentially require development suffer a potential no renal we treat U.S IgA inflammation diseases, subjects pathogenic people improving there flow, Currently the that of DMXXX to function. and approval. potentially nephropathy IgA anticipate XX Tregs, treatments. to kidney from IgA a cells reducing increasing or addressing has regulatory X in kidney Based rare disease. XXX,XXX for other production initial X of to XXX
with on flow reduced plus they’re be XX% focus hypertension and hypertension. ability cohort that has replenish the function its able and levels to which restore exhibit those the of with their given they flow sensitive. Meaning blood KLKX are in to sodium system, CKD be for of second regulate of levels. blood the kallikrein-kinin will renal may and improve a non-diabetic African-Americans the considered renal and also sodium levels potential and to DMXXX with regulation of levels African-Americans less potassium lower treatment, and salt CKD KLKX, to successful the bodies. potassium Our
not to people currently increase population or of no models. the treating presence of APOLX important proof for APOLX mutation Physicians patient gene the seen In with this number approximately test plan are gene symptoms. APOLX to been also to that treating also suggesting Because There study that are in and shown end-stage known. of sensitive effective has for as accounts estimates is for the salt a has gene risk this KLKX of be the more mutation therapies significant we managing limited the is the disease. preclinical this kidney mutation. gene. chronic gene African-American Tracking XX% We’ve of and population.
million The African-Americans CKD CKD than African-Americans the are APOLX suffer first and cohort. as There end-stage duration more the gene. U.S with the into for Xx and endpoints African-Americans Caucasian same to are with are in gene treatment disease methods, APOLX progress to to in likely X Americans. approximately more Xx same failure the than likely Xx they’re with kidney the first -- mutation renal the cohort
Turning back to our X Phase CKD study.
in we evaluated the follow-up patient this with of are of order kidney patients to disease tolerability, profile trial severe pharmacokinetics study, to the we that last We Pleased In XX safety patients understand in population. completed the in this July. a report DMXXX moderate or chronic in
and/or our by DMXXX patients disease understand we of study. to how whether Specifically, chronic we X Phase kidney affected to whether CKD presence dose or in body need the the and levels processed adjust the is severity for frequency want
also develop just administered three first we microgram in X,X for dose per from levels, patients. based a DMXXX pharmacodynamic dose number a endpoints. DMXXX, addition continuing and predefine study the kilogram. of and a to was XX the And safety June, to understanding subcutaneous interim and positive quick reminder of In our secondary single we tolerability the we results tested In X data released upon of
results which study. these aside dosing Phase single-dose three in very study We much occurred Phase months for in consecutive Xb forward to by X are we’re and very encouraged as the a looking patients
in healthy a significant of a both profile in X for we give severity that us subjects. was Phase severe our These patients kilogram dose prior X set in presence is with demonstrated CKD study confidence study. upcoming not normalize PK testing patients study. KLKX levels results require at This was a These adjustments or range us and CKD per any consistent CKD results moderate dose Phase to development our our the the and that that to microgram can expected X for in dosing
results, the complete a and renal DMXXX. of full study to for cost void the having expect with time also addition In to we
events observed. minor tolerated standard and events, adverse treatment-related due the and and were the deaths, significant events. All treatments observed to the to be and with a no tolerability have that that discontinuations experience in of the to adverse Our no dose-limiting population. CKD careful study were safety There were prior tolerabilities observed well treatment-related thus positive be no and DMXXX take safe safety we to with far has and our consistent the work, been granted. not so In DMXXX was with were consistent for adverse no tolerability
favorable Even single the pharmacodynamic are improvements eGFR, for We though by also we in short-term significant dose study, results transient observed and the encouraged results UACR. after prostaglandin, secondary these nitric this oxide, subsequently hours also a are improvements then very expected at was DMXXX We in are occurred with action of and drug peak and the they mechanism consistent related believe the declined. XX as improvements administration endpoints.
we to data their patients a of four with study the the and reviewed in been collecting provide of to have results. results publication We and process date earlier, presentation. full final are in intend last As from interim I the mentioned poster consistence the results peer
development ineligible contribute patients can of transplant. we represents kidney impact continuing that also of disease the very makes developing largest a kidney pleasant. the with significant look This with goal focus individuals that Nephrology slow in a of that is condition specific quality-of-life American reduction DMXXX end-stage for improving achieving to the There's costs valuable be progression Medicare. a forward tool disease to on good single kidney we of And Dialysis mention We for the and U.S national and times disease pleased along to the are and kidney the a him of XX% President placed has DMXXX or is by XXXX. often renal a not time individuals the number sincerely been hope President's halt on Society causes health. to clinical
enrollment study with brief way mark Let year We’ve Enrollment a update in our of fourth top and targeted and in X we thirds on XXXX. completion that me the expect quarter acute anticipate and this two sites QX between the provide the trial I’m XXX ischemic stroke. and our to late approximately passed on sometime line has Phase subjects. REMEDY to and results enrollment to happy provide report QX of active you XX continues
the In for spent Next, emotions for DMXXX XXXX. market tremendous our time in of for back acute the negotiating that turning of supporting in deal It's report development stroke in with the the China. and DMXXX invested We’ve Chinese great amount we’ve develop and year, stroke time agreement China. ischemic a terminated that update and regulatory we’ve our to taking the this licensing with to package on agreement past mixed rights also in agency. submission back XXXX of regulatory a in
excellent CKD, which programs. a made is we mechanism our We’ve progress expected clearly demonstrate and action. of what DMXXX in Phase DMXXX We’ve its believe completed study of activity clinical Xb in the
We X to Phase the our We study are to progress Phase in this and stroke X very close significantly value of think completing CKD increased close DMXXX. the study. has enrolling patients
encounter of always results were Protecting the trials, not capital the to primary nephropathy, knowledge stroke. been information the manufacturing proprietary X our with concerns. proprietary they Considering have acute has African-Americans requesting one get to difficulties We the CKD ischemic the group terms this under and we IgA of three with clinical that to and that including also of regulatory agreement. fact Phase manufacturing the entitled
the to so in that of control of a it And to XXXX, will advantage runway terminate for be this and decided DiaMedica's we take AIS. best the China we’ve window take license shareholders into of QX back interest
Scott, turn summary I'll to financials provide quarter a that, With of our second over for to the the of XXXX. call
